...in macular edema trial Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that THR-317...
...endpoint in a single-blind European Phase II trial in 70 patients with diabetic macular edema. THR-317...
...Vascular endothelial growth factor A Mary Romeo, Assistant Editor and Paul Bonanos, Associate Editor Acelarin (MTL-007, NUC-1031) THR-317 WP1066 Moleculin...

...ThromboGenics N.V. (Euronext:THR) said THR-317 was well tolerated with no dose-limiting toxicities (DLTs) reported in the...
...4 or 8 mg THR-317 given about one month apart. In anti-VEGF treatment-naïve patients, high-dose THR-317...
...Phase II trial is evaluating THR-317 plus Lucentis ranibizumab in about 72 patients with DME. THR-317...

...and 8 mg intravitreal THR-317 in about 50 patients. ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: THR-317...
...visit Status: Phase II started Milestone: Phase II data (1Q18) Chris Lieu ThromboGenics N.V. Placental growth factor (PGF) (PLGF) THR-317...